Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Egetis Therapeutics AB

LSE 0ABW
£5.56 - -%
Today share price
UK
Sector: Industrials Industry: Commercial Services & Supplies
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
-
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.43
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
-
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-

Upcoming events Egetis Therapeutics AB

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Egetis Therapeutics AB

Stock analysis Egetis Therapeutics AB

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
- 14.72
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
- -
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
- 4.28
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
- -
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
- -

Price change Egetis Therapeutics AB per year

3.13£ 7.28£
Min Max

Summary analysis Egetis Therapeutics AB

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Egetis Therapeutics AB

Revenue and net income Egetis Therapeutics AB

All parameters

About company Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Address:
Klara Norra Kyrkogata 26, Stockholm, Sweden, 111 22
Company name: Egetis Therapeutics AB
Issuer ticker: 0ABW
Country: UK
Exchange: LSE
Currency: £
Sector: Industrials
Industry: Commercial Services & Supplies
Site: https://www.egetis.com